Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

NCT00813228 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

76

Enrollment

NIH

Sponsor class

Conditions

Diabetes Mellitus Type 1
Diabetes Mellitus Type 2

Interventions

DRUG: Sitagliptin (Januvia)

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)